BioStem Technologies (OTC: BSEM) announced its participation in the Symposium on Advanced Wound Care (SAWC) Spring meeting, scheduled for April 8-12, 2026, in Charlotte, NC. The event is a key gathering for wound care professionals, and BioStem will use the platform to present its recently introduced Neox product line, which expands the company's portfolio of perinatal tissue allografts. This addition provides clinicians with multiple tissue formats to address varying clinical needs, handling preferences, and site-of-care requirements.
Jason Matuszewski, Chairman and CEO, emphasized the importance of contributing to clinical dialogue at SAWC. He stated that the expanded portfolio, which includes Neox, Clarix, VENDAJE, and American Amnion, is the most comprehensive suite of placental and umbilical cord tissue solutions backed by randomized clinical trials and real-world evidence. BioStem's booth will be open on April 9 (5:30-7:30 PM), April 10 (11:30 AM-2:00 PM), and April 11 (11:30 AM-2:00 PM) EST.
A key highlight is the Innovation Theater Lunch Symposium titled "A New Season in Wound Care: An Expanded Portfolio Grounded in Evidence" on April 9 from 12:15-1:45 PM in Room 207C. Featuring Dr. Wendy Weston, Dr. William Marston, and Dr. Herbert Slade, the session will discuss the science behind BioStem's birth tissue products, results from a randomized controlled trial on diabetic foot ulcers, and practical guidance for clinical integration. A live Q&A will follow.
BioStem will also present a scientific poster (number LR-020) in Exhibit Hall 1C, demonstrating its ongoing investment in clinical research. The company's participation underscores its commitment to medical education and expanding access to advanced healing technologies. Attendees are encouraged to visit the booth, attend the luncheon, and view the poster to learn more about BioStem's technologies and clinical data.
BioStem Technologies, Inc. (OTC: BSEM) is a biomedical innovator developing advanced allograft solutions from perinatal tissue. The company's proprietary processing technologies—BioRetain, CryoTek, and SteriTek—preserve tissue properties for clinical use. Its quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). More information is available at www.biostemtechnologies.com.
